Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Bayer
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05406219CT.gov A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Kidney Failure
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| bay2395840 (this asset) | Bayer | P1 | CC · 43 |
| Normal Human Serum Albumin | Anna Cruceta | P4 | BBB |
| Midodrine | Anna Cruceta | P4 | BB |
| Dexasone | Augusta University | P3 | BB |
| Doravirine | Thomas Benfield | P4 | BB |
| Envarsus Product | University of Alberta | P4 | BB |
| Lamivudine | Thomas Benfield | P4 | BB |
| Metformin | Cairo University | P4 | BB |
| Bortezomib | Augusta University | P2 | BB |
+42 more in the Kidney Failure cohort
Other indications for bay2395840
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetic Neuropathy | — | P2 | BB · 64 |
| Diabetes Mellitus | — | P2 | B · 57 |
| Peripheral Neuropathy | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. bay2395840 in Kidney Failure. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bay2395840-kidney-failure
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →